Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain
David Spanswick(Australian Regenerative Medicine Institute), Wendy L. Imlach(Australian Regenerative Medicine Institute), Marie Guillemot(Evotec (United States)), Andrew Whyment(University of Warwick), Adam Campbell-Galland(University of Warwick), Kelly O'Sullivan(Australian Regenerative Medicine Institute), Andrew J. Gearing(Leo Pharma (Australia)), Matilde P. Caldeira Borges da Cruz(University of Warwick), Fei-Yue Zhao(University of Warwick), David Kenley(Leo Pharma (Australia)), François Autelitano(Evotec (Germany)), Haifeng Wei(University of Warwick), Anthony E. Pickering
Cited by 0
Related Papers
Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief
|Science Translational Medicine|2017|240
Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a
|Scientific Reports|2017|139
Identification of Novel Tumor-Associated Cell Surface Sialoglycoproteins in Human Glioblastoma Tumors Using Quantitative Proteomics
|PLoS ONE|2014|42
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma
|Investigational New Drugs|2019|39